- Home
- RCKT vs SLP Comparison
RCKT vs SLP Comparison
Compare RCKT & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | SLP |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.6M | 418.4M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | RCKT | SLP |
|---|---|---|
| Price | $3.16 | $14.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $30.27 | $25.00 |
| AVG Volume (30 Days) | ★ 2.2M | 360.0K |
| Earning Date | 02-26-2026 | 01-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $78,676,000.00 |
| Revenue This Year | N/A | $2.64 |
| Revenue Next Year | N/A | $6.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.70 |
| 52 Week Low | $2.19 | $12.39 |
| 52 Week High | $11.27 | $37.67 |
Technical Indicators
Market Signals| Indicator | RCKT | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 27.90 |
| Support Level | $3.00 | $14.08 |
| Resistance Level | $3.63 | $21.01 |
| Average True Range (ATR) | 0.20 | 0.87 |
| MACD | -0.07 | -0.63 |
| Stochastic Oscillator | 14.08 | 9.16 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.